We reach more than 65,000 registered users in Dec!! Register Now
Groundbreaking Antidiabetic Compound Unveiled: HPH-15 Reduces Blood Glucose Level and Combats Fat Accumulation
- January 20, 2025
- 1 Views
- 0 Likes
- 0 Comment
Kumamoto University scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marking a significant leap in diabetes treatment innovation.
Type 2 diabetes, a condition affecting millions worldwide, is often accompanied by complications like fatty liver and insulin resistance, which challenge current treatment methods. The research team, led by Visiting Associate Professor Hiroshi Tateishi and Professor Eiichi Araki, has identified HPH-15 as a promising alternative to existing medications like metformin.The study, published in Diabetologia, a top journal in the field of diabetes, demonstrates that HPH-15 outperforms metformin by activating AMP-activated protein kinase (AMPK)—a critical protein regulating energy balance—at lower doses. HPH-15 not only improved glucose uptake in liver, muscle, and fat cells but also significantly reduced fat accumulation in high-fat diet (HFD)-induced obese mice. Unlike metformin, HPH-15 exhibited additional antifibrotic properties, potentially addressing liver fibrosis and other complications often seen in diabetes patients.Key findings include:
- Enhanced Efficacy: HPH-15 activated AMPK and promoted glucose uptake at concentrations 200 times lower than metformin.
- Fat Reduction: The compound decreased subcutaneous fat by 44% and mitigated fatty liver more effectively than metformin in preclinical trials.
- Safety Profile: Lactic acid production, a concern with metformin, was either comparable or lower with HPH-15, suggesting reduced risks of lactic acidosis.
List of Referenes
- Tsugumasa Toma, Nobukazu Miyakawa, Yuiichi Arakaki, Takuro Watanabe, Ryosei Nakahara, Taha F. S. Ali, Tanima Biswas, Mikio Todaka, Tatsuya Kondo, Mikako Fujita, Masami Otsuka, Eiichi Araki, Hiroshi Tateishi. An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models. Diabetologia, 2024; 67 (11): 2568 DOI: 10.1007/s00125-024-06260-y
Cite This Article as
No tags found for this post